July 17-20, 2027
Marriott Marquis San Diego Marina
San Diego, California

Scientific Committee Cochairs

Lillian L. Siu, Princess Margaret Cancer Centre, Toronto, Ontaria, Canada
Patricia M. LoRusso, Yale School of Medicine, New Haven, Connecticut
Keith T. Flaherty, Harvard Medical School, Boston, Massachusetts
Timothy A. Yap, The University of Texas MD Anderson Cancer Center, Houston, Texas

Join us in San Diego from July 17-20, 2027, for the second AACR Drug Discovery and Development (AACR D3) conference. The inaugural program launched in 2026 was developed to redefine the future of oncology drug development by challenging conventional paradigms and catalyzing innovation across disciplines. AACR D3 2026 far exceeded expectations in terms of attendance, abstract submissions, biotech applications, and exhibits – gathering a diverse and influential community of thought-leaders from biotech, pharma, academia, regulatory agencies, technology, venture capital, and patient advocacy, to spark bold ideas and foster transformative collaborations.

Far beyond traditional didactic sessions, AACR D3 2027 will again feature immersive and interactive formats to create dynamic networking opportunities and facilitate real-time problem-solving. Attendees will explore cutting-edge science, novel technologies, and emerging frameworks that promise to revolutionize how cancer therapies are discovered, developed, and delivered.

Objectives:

• Highlight emerging drug mechanisms and first-in-class targets
• Examine the impact of breakthroughs in cellular and molecular biology
• Showcase transformative tools, platforms, and AI-driven approaches in drug discovery
• Advance next-generation clinical trial designs and innovative endpoints
• Explore forward-thinking regulatory pathways to accelerate development timelines
• Foster strategic partnerships through curated networking experiences
• Facilitate networking and professional development opportunities to inspire and support oncology-focused entrepreneurs

Scientific Committee Members:

Benedito A. Carneiro, Brown University, Providence, Rhode Island
Raffaele Colombo, Zymeworks, Vancouver, British Columbia, Canada
Danette L. Daniels, Foghorn Therapeutics, Cambridge, Massachusetts
Paul Haluska, Bayer, Whippany, New Jersey
Norbert Kraut, Boehringer Ingelheim, Vienna, Austria
Jonathan Lim, ERASCA, San Diego, California
Lilli Petruzzelli, Genentech, San Francisco, California
Michael Pourdehnad, Bristol Myers Squibb, Princeton, New Jersey
Mike Sathekge, University of Pretoria, Pretoria, South Africa
Maurizio Scaltriri, AstraZeneca, Gaitherburg, Maryland
Kurt A. Schalper, Yale University, New Haven, Connecticut
Andrew M. Scott, Olivia Newton-John Cancer Research Institute, Heidelberg, Australia
William R. Sellers, Broad Institute of MIT and Harvard, Cambridge, Massachusetts
Geoffrey I. Shapiro, Dana-Farber Cancer Institute, Boston, Massachusetts
Hong Shen, China Innovation Center of Roche (CICoR), Shanghai, China
Yu Shyr, Vanderbilt University Medical Center, Nashville, Tennessee
Naoto T. Ueno, University of Hawai’i Cancer Center, Honolulu, Hawaii
Paul Workman, The Institute of Cancer Research, London, United Kingdom
Li Yan, US Chinese Anti-Cancer Association, Martinez, California

Additional committee members to be announced